Ongoing clinical trials performed in KRAS-mutated nonsmall cell lung (NSCLC) patients
| clinicaltrials.gov identifier | Phase | Tumour type | |
| MEK inhibitors | |||
| Selumetinib + docetaxel (versus docetaxel) | NCT01933932 | III | NSCLC |
| Trametinib + chemoradiation | NCT01912625 | I | Unresectable NSCLC |
| PD-0325901 + palbociclib | NCT02022982 | I/II | NSCLC and other solid tumours |
| MEK162 + BYL719 | NCT01449058 | Ib | All solid tumours |
| MEK162 | NCT01885195 | II | All solid and haematological malignancies |
| MEK162 + RAF265 | NCT01352273 | I | All solid tumours |
| MEK162 + erlotinib | NCT01859026 | I | NSCLC |
| PD-0325901 + dacomitinib | NCT02039336 | I | NSCLC |
| Other | |||
| BIND-014 | NCT02283320 | II | NSCLC |
| Bortezomib | NCT01833143 | II | NSCLC |
| Retaspimycin HCI (IPI-504) + everolimus | NCT01427946 | Ib/II | NSCLC |
| VS-6063 (defactinib) | NCT01951690 | II | NSCLC |
| Wild-type reovirus + paclitaxel + carboplatin | NCT00861627 | II | NSCLC |
| Abemaciclib (LY2835219) | NCT02152631 | III | NSCLC |